Resolute Advisors’s AstraZeneca AZN Stock Holding History

Resolute Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-50	Closed	–	–	527
2021 Q2	$0	Buy	+50	New	+$5.49K	﹤0.01%	493

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Resolute Advisors's AZN Position: Q3 2021 in Review

Resolute Advisors sold out of AstraZeneca (AZN) in Q3 2021, closing a stake of 50 shares.

Resolute Advisors first reported a position in AZN in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 905 funds tracked by Wall St. Rank hold AZN as of Q3 2021.

Resolute Advisors reported no remaining AstraZeneca position as of Q3 2021 after selling out during the quarter.
Resolute Advisors sold 50 AstraZeneca shares in Q3 2021.
Resolute Advisors first reported a position in AstraZeneca in Q2 2021 and held it in 1 quarter.
Resolute Advisors's AstraZeneca position peaked at $0 in Q2 2021.
905 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2021.

Based on Resolute Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.